Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.60 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL27288892 | 0.92 | HCAR3 (0.56) | TSHRCYP3A4HCAR3KAT2BHTT | |
| SCHEMBL978709 | 0.85 | TSHR (0.62) | TSHRCYP3A4HCAR3KAT2BALDH1A1 | |
| SCHEMBL27872705 | 0.83 | TSHR (0.60) | TSHRCYP3A4KAT2BALDH1A1MAPT | |
| SCHEMBL2371809 | 0.83 | TSHR (0.60) | TSHRCYP3A4KAT2BALDH1A1KCNMA1 | |
| SCHEMBL17546158 | 0.83 | KAT2B (0.60) | TSHRCYP3A4KAT2BALDH1A1MAPT | |
| SCHEMBL7086572 | 0.83 | TSHR (0.60) | TSHRCYP3A4KAT2BALDH1A1MAPT | |
| SCHEMBL28284771 | 0.83 | TSHR (0.60) | TSHRCYP3A4KAT2BALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL3009620 | 0.81 | KAT2B (0.61) | TSHRCYP3A4KAT2BALDH1A1MAPT | |
| SCHEMBL10534498 | 0.81 | HTT (0.71) | HCAR3HTTALDH1A1MAPTMAPK1 | |
| SCHEMBL365880 | 0.81 | MAPT (0.60) | TSHRHCAR3HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2020257385-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-9974307-B2 | Composition and method for controlling pests | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9883675-B2 | Method for controlling pests | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-9854805-B2 | Composition and method for controlling pests | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2400961-B1 | MEDICINE COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-9723835-B2 | Pest control composition and method for controlling pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| WO-2010032461-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND | 武田薬品工業株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
| EP-1325910-B1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| WO-2002036580-A9 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002036580-A2 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
| US-3931215-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | TSHR 3606/4885CYP3A4 2837/4885HCAR3 578/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | TSHR 3388/4885CYP3A4 3402/4885HCAR3 2881/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | TSHR 396/4885CYP3A4 285/4885HCAR3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.